← Back to Search

RECELL for Carbon Dioxide Laser Recovery

Phase 4
Recruiting
Led By Joseph Molnar, MD, PhD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients undergoing facelift with perioral CO2 laser treatment
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 3
Awards & highlights

Study Summary

This trial will test whether using a person's own cells to treat side effects of CO2 laser treatment can reduce healing time.

Who is the study for?
This trial is for adults over 18 with a light skin tone (Fitzpatrick Score 1 or 2) who are getting a facelift and CO2 laser treatment around the mouth. It's not for those who've had perioral CO2 laser resurfacing before or have allergies to the ReCell system components.Check my eligibility
What is being tested?
The study tests if using ReCell, which involves applying your own cells after they're prepared through special processes, can reduce side effects from CO2 laser treatments and speed up healing of the skin.See study design
What are the potential side effects?
While specific side effects aren't listed, generally procedures like this could cause redness, swelling, sensitivity at the application site, infection risk or an allergic reaction to the preparation used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am getting a facelift and CO2 laser treatment around my mouth.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 3
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in FACE-Q scale scores
Change in Skin sensitivity scores - burning
Change in Skin sensitivity scores - itching
+4 more
Secondary outcome measures
Healing within 2 weeks post-op

Trial Design

2Treatment groups
Experimental Treatment
Group I: Right receives ReCell (A)Experimental Treatment1 Intervention
Right perioral area of face receives ReCell/ Left receives saline
Group II: Left receives ReCell (B)Experimental Treatment1 Intervention
Left perioral area of face receives ReCell/ Right receives saline
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ReCell
2015
Completed Phase 4
~30

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Carbon Dioxide (CO2) lasers work by emitting a concentrated beam of light that vaporizes the water in skin cells, leading to the removal of thin layers of skin with high precision. This process stimulates collagen production and skin remodeling, which is beneficial for treating various skin conditions. However, CO2 laser treatments can cause side effects such as prolonged healing times and skin irritation. Autologous cell suspension, which involves applying a patient's own cells prepared through enzymatic and mechanical methods, can enhance healing and reduce these side effects by promoting faster re-epithelialization and reducing inflammation. Understanding these mechanisms is crucial for patients as it helps them make informed decisions about their treatment options and manage their expectations regarding recovery and outcomes.
A Double-Blind Randomized Sham-Controlled Trial to Evaluate the Efficacy of Fractional Carbon Dioxide Laser Therapy on Genitourinary Syndrome of Menopause.Retrospective Matched Case-Control Study on the Use of CO<sub>2</sub> Laser for the Treatment of Nonhealing Diabetic Foot Ulcers: The DULCIS-2 (Diabetic ULcer, CO<sub>2</sub> Laser, and Infections) Study.[Treatment of Hailey-Hailey disease with carbon dioxide laser vaporization].

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,250 Previous Clinical Trials
1,007,143 Total Patients Enrolled
Avita MedicalIndustry Sponsor
15 Previous Clinical Trials
640 Total Patients Enrolled
Joseph Molnar, MD, PhDPrincipal InvestigatorWake Forest University Health Sciences
2 Previous Clinical Trials
17 Total Patients Enrolled

Media Library

Left receives ReCell (B) Clinical Trial Eligibility Overview. Trial Name: NCT05386368 — Phase 4
Carbon Dioxide Laser Research Study Groups: Left receives ReCell (B), Right receives ReCell (A)
Carbon Dioxide Laser Clinical Trial 2023: Left receives ReCell (B) Highlights & Side Effects. Trial Name: NCT05386368 — Phase 4
Left receives ReCell (B) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05386368 — Phase 4
~5 spots leftby Dec 2025